Skip to content
DataLookout
Menu

NCT07699523

The Effects of Midazolam, Dexmedetomidine, and Esketamine on Bispectral Index and Raw Electroencephalogram in Patients Under Propofol-Remifentanil Baseline Anesthesia

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 11 words
    • Study sites: 1 to 2
    • Start date changed from estimate of Jun 30, 2026 to Jul 14, 2026
    • Secondary endpoints: details revised at 1 of 7 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change in Bispectral Index (BIS) value from the pre-intervention baseline
Timeframe: Baseline and 5, 10, 15, 20, 25, 30 minutes after adjunct drug administration

Secondary (7)

Change in mean arterial pressure from pre-intervention baseline
Change in heart rate from pre-intervention baseline
Time from discontinuation of anesthetic drugs to airway device removal
Time to Aldrete score of 10 in the post-anesthesia care unit
Brice questionnaire assessment
Show 2 moreShow less
Postoperative pain score
Postoperative analgesic medication use

Arms and interventions

Control GroupActive comparator

Participants receive standardized propofol-remifentanil total intravenous anesthesia without administration of the study adjunct anesthetic drug.

Midazolam GroupExperimental

Participants receive standardized propofol-remifentanil total intravenous anesthesia plus midazolam according to the study protocol.

Dexmedetomidine GroupExperimental

Participants receive standardized propofol-remifentanil total intravenous anesthesia plus dexmedetomidine according to the study protocol.

Esketamine GroupExperimental

Participants receive standardized propofol-remifentanil total intravenous anesthesia plus esketamine according to the study protocol.

Drugs: Midazolam, Dexmedetomidine, Esketamine, Propofol, Remifentanil

Sites

2 sites in 1 country